Phase 3 N=35 Minimal Effective Dose of Hyperbaric Spinal Bupivacaine for Saddle Block
Perianal Surgery
Primary: Minimal Effective Dose of Hyperbaric Bupivacaine — 1.9 milligrams
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Prospective Randomized Trial of Dermabond Prineo in Total Knee Arthroplasty
Wound Heal
Primary: Modified Hollander Cosmesis Scale — 30; 0; 0; 23 Participants
Phase 2 N=259 EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
Edematous Fibrosclerotic Panniculopathy · Cellulite
Primary: Number of Participants That Were 2-level Composite (CR-PCSS and PR-PCSS) Responders During the Observation Phase — 19; 0; 16; 0 Participants
Phase 4 N=23 EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty
Pain
Primary: Maximum Plasma Concentration (Cmax) — 499; 775 ng/mL
Phase 4 N=154 Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga
Type 2 Diabetes Mellitus
Primary: Number of Participants Achieving Drug-free Diabetes Remission in the Experimental Group Compared to the Control Group — 19; 13 Participants
N/A N=437 Using Bluetooth Beacon Technology to Reduce Distracted Pedestrian Behavior
Health Behavior
Primary: Percentage of Street Crossings Distracted — 75; 74; 74 per cent of crossings distracted
Phase 2 N=60 Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Leukemia, Chronic Myelogenous
Primary: Percentage of Participants With Major Molecular Response (MMR) at Month 12 — 55.0 Percentage of participants — p=<0.0001
Phase 2 N=207 Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
Venous Thromboembolism
Primary: Percentage of Participants With Total Venous Thromboembolism — 19; 29; 17 Participants
N/A N=1,026 Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"
Type 2 Diabetes Mellitus
Primary: Percentage of Participants Who Had One or More Adverse Events — 5.93 Percentage of Participants
Phase 3 N=121 Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence
Nicotine Dependence · Nicotine Withdrawal
Primary: Nicotine Withdrawal and Craving — p=0.07
Phase 4 N=7 Neural Mechanisms of Disulfiram Effects
Alcohol Use Disorder
Primary: Alcohol Use — 0 days
Phase 2 N=96 In Vivo Patient Preoperative Skin Prep Persistence
Bacterial Recovery of Skin Flora Post-Product Application
Primary: Measurement of Skin Flora Recovery Post-prep Application Relative to Baseline — 0.91; 2.81; 0.59; 2.96 Log10 CFU/cm^2 — p=<0.0001
Phase 3 N=1,946 In Vivo Efficacy Study of Patient Preoperative Preps
Bacterial Reduction Post-product Application
Primary: Responder Rate — 159; 165; 163; 5 Participants — p=<0.0001
N/A N=120 Clinical Comfort Evaluation of Two Marketed Spherical Contact Lenses
Astigmatism
Primary: Comfort at Insertion — 8.7; 8.5 units on a scale
Phase 4 N=245 A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
Psoriatic Arthritis
Primary: Percentage of Participants Achieving Minimal Disease Activity (MDA) (Non-responder Imputation [NRI]) (Part 1) — 13.1; 41.5 percentage of participants — p=< 0.001